Pheast’s new CEO on how its ‘don’t eat me’ platform could deliver next-gen precision immunotherapies

Jacopo Leonardi’s latest venture is in the burgeoning field of macrophage inhibitors that could target a wide range of cancers.

By Taren Grom • Feb. 17, 2023

Despite rare disease market growth, pharma leaders see development obstacles ahead

Investment in rare disease research is increasing, but a recent poll of PharmaVoice readers found that roadblocks remain.

By Karissa Waddick • Feb. 17, 2023

Explore the Trendline➔

Big Pharma Business Strategies

Large pharmas are consistently tasked with the goal of growth. But in recent years, the upward trajectory has been littered with new hurdles. 

By PharmaVoice staff

Nectin’s Keytruda combo could fill gaps in immuno-oncology’s treatment paradigm

The Israeli biotech just entered into a collaboration with Merck to develop its own checkpoint inhibitor alongside the bestselling cancer treatment.

By Michael Gibney • Feb. 16, 2023

Woman of the Week: Bristol Myers Squibb’s Ester Banque

The 30-year veteran is heading up the “transformation” of one of the pharma giant’s most important therapeutic portfolios: hematology.

By Taren Grom • Feb. 15, 2023

Managing for resilience: Passage’s ups and downs in gene therapy

After a rocky year, Passage Bio’s CEO is focused on helping the rare disease specialist bounce back.

By Meagan Parrish • Feb. 15, 2023

The post-COVID outlook for decentralized clinical trials

The COVID-19 pandemic had many pharmas turning to DCTs as a way to keep the clinical wheel turning. Can the industry keep that flexibility going forward? 

By Michael Gibney • Feb. 14, 2023

For Complement’s CEO, storytelling could be just as critical as data

Dr. Rafiq Hasan has his sights on bringing lessons learned at Bayer to ophthalmology-focused Complement Therapeutics.

By Alexandra Pecci • Feb. 14, 2023

Why are there gaps in mental healthcare? Often it’s flawed trial methodology

Sunovion Pharmaceuticals has developed a more precise way to track symptoms that could be broadly adopted across the industry.

By Kelly Bilodeau • Feb. 10, 2023

Rocket Pharmaceuticals is ready for liftoff in the rare disease space

With two rare disease products on the launch pad for FDA submission in 2023 and a growing pipeline, Rocket is fueled for its next era of growth.

By Taren Grom • Feb. 10, 2023

The unique playbook of Biohaven’s CEO

Vlad Coric’s offbeat business strategy paid off once with a Pfizer buyout. Can he do it again?

By Meagan Parrish • Feb. 8, 2023

Woman of the Week: KaliVir Immunotherapeutics’ Helena Chaye

The triple threat CEO — scientist, lawyer and biotech pro — thinks she’s discovered a key to curing a wide range of cancers.

By Taren Grom • Feb. 8, 2023

Leaps in vax tech — researchers find new ways to tackle old problems like fungal infections and cancer

A growing number of fungal infections has caused a stir in the research community, and new vaccines could be the answer down the road.

By Michael Gibney • Feb. 7, 2023

Entact Bio’s CEO is leading the company out of stealth and into a new age of protein enhancement

Victoria Richon’s latest venture is in the burgeoning field of protein-enhancing drugs that could target a range of diseases.

By Kelly Bilodeau • Feb. 6, 2023

Woman of the Week: Bayer’s Dr. Yesmean Wahdan

The VP of medical affairs and women’s health is focused on an audacious goal to meet the needs of 100 million women globally.

By Taren Grom • Feb. 1, 2023

Astria Therapeutics’ edge in an ultra-rare disease

With positive early phase data, CEO Jill Milne is aiming to bring an improved preventative option to patients with hereditary angioedema.

By Taren Grom • Feb. 1, 2023

Weight loss drugs: the promise and pitfalls

GLP-1 agonists are dominating the anti-obesity scene — but hurdles remain to their uptake.

By Kelly Bilodeau • Jan. 30, 2023

A biotech CEO’s favorite ‘F’ word

At SFA Therapeutics, patients are the “focus” of Ira Spector’s approach to changing the course of autoimmune disease.

By Taren Grom • Jan. 26, 2023

Gilead’s commercial chief on why 2023 will be a ‘coming out’ year

With a rapidly expanding oncology pipeline and a new approval in HIV, Johanna Mercier discusses Gilead’s quest to transform.

By Meagan Parrish • Jan. 26, 2023

Report reveals murky picture of clinical trial diversity gains

Data discrepancies between study phases and indications could provide clues about why some trials have better racial and ethnic diversity than others.

By Alexandra Pecci • Jan. 24, 2023

Already on a roll in oncology, Astellas hunts for big wins in other areas

With two potential first-in-class drug launches on the horizon, and a budding gene therapy business, Astellas believes this year could be a major inflection point. 

By Karissa Waddick • Jan. 23, 2023

A Moderna tie-up ushers in new era for CytomX

The antibody-focused company followed up a tough year with big partnerships to keep the ball rolling.

By Michael Gibney • Jan. 18, 2023

Woman of the Week: Genetika+’s Talia Cohen Solal

The CEO is aiming to build a “brain-in-a-dish” to treat all patients for better mental health outcomes.

By Taren Grom • Jan. 18, 2023

Pro sports’ COVID protocols led to real-world data impacts for pharma

After years of pioneering new methods for using data and technology to improve patient health outcomes, IQVIA’s Christina Mack is on the cusp of a research revolution.

By Karissa Waddick • Jan. 16, 2023

Space — the next frontier in drug development

Merck, Bristol Myers Squibb and others are taking small R&D steps in space that could lead to giant leaps for patients.

By Kelly Bilodeau • Jan. 12, 2023

Woman of the Week: Form Bio’s Claire Aldridge

The chief strategy officer of Form Bio is harnessing the new company’s computing power and bioinformatics to spur a genomic revolution.

By Taren Grom • Jan. 11, 2023